Get introduced to the
most exciting companies in
our portfolio.

BigHat Biosciences develops antibody and protein therapeutics using machine learning, synthetic biology, and automated laboratory experimentation. Its Milliner platform combines computational models with high-throughput wet-lab testing to design, synthesize, characterize, and optimize antibodies across multiple properties relevant to therapeutic development. The company also provides antibody engineering, data generation, and model development services for biopharmaceutical and artificial intelligence research teams. Its Reccy Antibody Design Studio coordinates models and biological datasets to connect computational design with experimental results and support iterative development. BigHat Biosciences also develops its own therapeutic pipeline, including antibody-drug conjugates and T-cell engagers for applications in oncology and immunology.